Business Context and Reporting Period
This Form 8-K filing by AntriaBio, Inc. (not Rezolute, Inc.) reports on events occurring on December 7, 2015, and an initial close of a financing round on December 10, 2015. The company, incorporated in Delaware, announced the initial close of an offering of Series A Preferred Stock.
Key Financial Metrics
- Gross Cash Proceeds: $2,000,115 received from the initial close.
- Shares Issued: 1,025,699 shares of Series A Preferred Stock.
- Price Per Share: $1.95.
- Placement Agent Fees: Approximately $105,000 paid at the initial close (7% of aggregate purchase price).
- Warrants Issued: Approximately 64,000 warrants issued to the placement agent with an exercise price at a 20% premium to the purchase price.
- Dividend Rate: 6% annual cumulative dividend payable in stock.
Material Changes
The primary material change is the entry into a definitive agreement for a Series A Preferred Stock offering. The company filed a Certificate of Designations with the State of Delaware on December 7, 2015, establishing the rights and preferences of the new security class. This represents a significant capital raise event and a modification to the rights of security holders.
Terms, Outlook, and Risks
- Conversion Terms: Shares are convertible to Common Stock at a 1:1 ratio, subject to weighted average anti-dilution adjustments if future securities are issued at a lower price.
- Liquidation Preference: Holders are entitled to the purchase price plus accrued dividends before common stockholders. In a "Deemed Liquidation Event" (e.g., merger or asset sale), this preference applies unless the transaction value exceeds 3x the conversion price.
- Mandatory Conversion: Automatic conversion occurs upon a successful NASDAQ/NYSE MKT listing (subject to price thresholds) or an underwritten public offering raising at least $15 million at a price of 155% of the conversion price.
- Maturity: The stock matures 10 years after issuance, at which point the company must redeem it for cash.
- Registration Rights: The company must register the underlying common stock within 90 days or pay a 1% monthly cash penalty to holders.
- Risks: The securities were sold under Section 4(a)(2) and Rule 506 exemptions and are not registered; they cannot be resold in the U.S. without registration or an exemption.
Investor Verification Checklist
- Verify the total number of shares outstanding and the fully diluted capitalization post-issuance.
- Confirm the company's ability to meet the 90-day registration requirement to avoid the 1% monthly cash penalty.
- Review the specific anti-dilution formula impact on future fundraising rounds.
- Assess the company's cash runway given the $2 million raised versus operational burn rates.
- Check for any subsequent closings of the $15 million total offering capacity.